Bitte beachten Sie: Suchbegriffe unter einer Länge von 3 Buchstaben werden ignoriert.
267 Treffer:
1.
A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 Versus Investigator's Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants With Metastatic Castration-resistant
NCT Heidelberg » Für Ärzte » Studien » Urogenitale Tumoren » Prostatakarzinom
Datum: 2026-04-04
2.
A Randomised, Open-label, Phase 3 Trial Comparing the Efficacy and Safety of OSE2101 Versus Docetaxel in HLA-A2 Positive Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) With Secondary Resistance to Immune Checkpoint Inhibitor
NCT Heidelberg » Für Ärzte » Studien » Thorakale Tumoren » Bronchialkarzinom
Datum: 2026-04-04
3.
A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Ex
NCT Heidelberg » Für Ärzte » Studien » Thorakale Tumoren » Bronchialkarzinom
Datum: 2026-04-04
4.
A Randomized, Double Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012+Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide vs Atezolizumab in Combination With Carboplatin Plus Etoposide as First-Line Therapy in Partic
NCT Heidelberg » Für Ärzte » Studien » Thorakale Tumoren » Bronchialkarzinom
Datum: 2026-04-04
5.
SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ?5
NCT Heidelberg » Für Ärzte » Studien » Thorakale Tumoren » Bronchialkarzinom
Datum: 2026-04-04
6.
A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination With Carboplatin Plus Pemetrexed Versus Platinum Plus Pemetrexed or Nivolumab Plus Ipilimumab in Participants With Unresectable Pleural Mesothelioma (e
NCT Heidelberg » Für Ärzte » Studien » Thorakale Tumoren » Pleuramesotheliom
Datum: 2026-04-04
7.
A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Me
NCT Heidelberg » Für Ärzte » Studien » Thorakale Tumoren » Bronchialkarzinom
Datum: 2026-04-04
8.
A Randomized, Double-blind, Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer (HARMONi-3)
NCT Heidelberg » Für Ärzte » Studien » Thorakale Tumoren » Bronchialkarzinom
Datum: 2026-04-04
9.
A Platform Study of RAS(ON) Inhibitor Combinations in Patients with RAS-Mutated Non-Small Cell Lung Cancer (NSCLC)
NCT Heidelberg » Für Ärzte » Studien » Thorakale Tumoren » Bronchialkarzinom
Datum: 2026-04-04
10.
Beamion LUNG 2: A Phase III, Open-label, Randomized, Active-controlled, Multi-centre Trial Evaluating Orally Administered Zongertinib (BI 1810631) Compared With Standard of Care as First-line Treatment in Patients With Unresectable, Locally Advanced or Me
NCT Heidelberg » Für Ärzte » Studien » Thorakale Tumoren » Bronchialkarzinom
Datum: 2026-04-04